Radhakrishnan Divya M, Goyal Vinay
Senior Research Officer,Department of Neurology, All India Institute of Medical Sciences, New Delhi.
Professor, Department of Neurology, All India Institute of Medical Sciences, New Delhi.
J Assoc Physicians India. 2018 Jun;66(6):95-96.
Levosulpiride is a newer prokinetic agent with increasingly extensive use in India by general physicians. Levosulpiride selectively inhibits gut and central D2 receptors and is associated with various movement disorders like- tremor, Parkinsonism, dyskinesias and rarely dystonia. We report 7 cases of levosulpirideinduced dystonia at our institute. Though all patient had at least 50% improvement after discontinuation of levosulpiride, none had complete recovery at mean follow up of 5.5 months. Through this article we want to highlight extrapyramidal side effects of levosulpiride, need of its awareness among physicians.
左舒必利是一种新型促动力药物，在印度被普通医生越来越广泛地使用。左舒必利选择性抑制肠道和中枢D2受体，并与各种运动障碍有关，如震颤、帕金森综合征、运动障碍，很少引起肌张力障碍。我们在我院报告了7例左舒必利引起的肌张力障碍病例。虽然所有患者在停用左舒必利后至少有50%的改善，但在平均5.5个月的随访中，没有一例完全康复。通过本文，我们想强调左舒必利的锥体外系副作用，以及医生对其认识的必要性。
